These modifications aim to minimize the potential risk for allo-TCR-mediated GvHD (eliminating TCR-mediated recognition of histocompatibility antigens that can lead to GvHD) and diminish SLAMF7-mediated fratricide. The gene discussed is SLAMF7; the disease is graft versus host disease.